// Auto-generated - do not edit
export const substanceName = "Dexmethylphenidate";
export const sources = [{"id":"drugbank","fileName":"DRUGBANK - Dexmethylphenidate.md","displayName":"DrugBank","size":23374},{"id":"protestkit","fileName":"PROTESTKIT - Dexmethylphenidate.json","displayName":"Protest Kit","size":1495},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - Dexmethylphenidate.md","displayName":"TripSit Factsheets","size":618},{"id":"wikipedia","fileName":"WIKIPEDIA - Dexmethylphenidate.md","displayName":"Wikipedia","size":16507}];
export const contents: Record<string, string> = {
  "drugbank": `# Dexmethylphenidate
*Source: https://go.drugbank.com/drugs/DB06701*

## Overview

### Description

This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.

### Background

Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002
2
. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant
5
. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Label
,
2
. The d-isomer is thought to have greater effect with fewer side effects than the l-isomer or the racemic mixture
2
.

### Indication

Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment
4
,
Label
.

### Pharmacodynamics

Dexmethylphenidate is the d-enantiomer of methylphenidate
Label
. This enantiomer is more pharmacologically active than the racemic mixture and may block norepinephrine and dopamine reuptake in synapses
Label
.

### Mechanism of Action

Sodium-dependent dopamine transporter
Inhibitor
Sodium-dependent noradrenaline transporter
Inhibitor

### Absorption

Taking dexmethylphenidate with or without food does not affect patients in a clinically relevant way
4
. 90% of an oral dose is absorbed
Label
but as a result of hepatic first pass metabolism, oral bioavailability of dexmethylphenidate is 23% compared to l-methylphenidate with an oral bioavailability of 5%
4
. Maximum concentration is generally reached in 1-1.5 hours
Label
.

### Metabolism

Dexmethylphenidate is metabolised to the inactive metabolite ritalinic acid by carboxylesterase 1A1 in the liver
Label
,
1
. Other minor pathways metabolise dexmethylphenidate to the inactive metabolites 6-oxo-methylphenidate and p-hydroxy-methylphenidate which are de-esterified and conjugated into other unknown metabolites
4
.
Hover over products below to view reaction partners
Dexmethylphenidate
Ritalinic acid
p-hydroxy-methylphenidate
6-oxo-methylphenidate

### Half-life

The mean terminal half life is approximately 2.2 hours
Label
. However other studies have shown 3.8-3.9 hours
3
, or 5.96 hours after intravenous administration and 5.69 hours following an oral dose
4
.

### Toxicity

There is no difference in effect across genders
3
,
Label
. The difference in effect across racial groups, patients under 6 years, renal impairment, hepatic impairment, pregnancy, lactation, and geriatric patients has not been well studied. Patients with renal impairment are not expected to need dose adjustment as the drug is not mainly cleared renally
Label
. Animal studies in pregnant and lactating rats showed delayed fetal skeletal ossification, and reduced weight gain in male offspring
Label
. Due to these studies, caution must be exercised and the benefits and risks of taking this drug must be weighed
Label
. It is unlikely that dexmethylphenidate is carcinogenic but B6C3F1 mice, which are sensitive to the development of hepatic tumours, developed hepatoblastomas at 2 times the maximum recommended human dose
Label
. Methylpheidate was not found to be mutagenic but is weakly clastogenic in Chinese Hamster Ovary cells
Label
. Methylphenidate does not impair fertility in animal studies
Label
.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Dexmethylphenidate is combined with 1,2-Benzodiazepine.
Acebutolol
Dexmethylphenidate may decrease the antihypertensive activities of Acebutolol.
Aceclofenac
The risk or severity of hypertension can be increased when Dexmethylphenidate is combined with Aceclofenac.
Acemetacin
The risk or severity of hypertension can be increased when Dexmethylphenidate is combined with Acemetacin.
Acenocoumarol
The serum concentration of the active metabolites of Acenocoumarol can be increased when Acenocoumarol is used in combination with Dexmethylphenidate.

### Food Interactions

Avoid alcohol. Alcohol inhibits the metabolism of dexmethylphenidate.
Take with or without food.

## Chemical Information

**DrugBank ID:** DB06701

**Synonyms:** (+)-threo-methylphenidate
d-threo-methylphenidate
D-TMP
Dexmethylphenidate
Dexméthylphénidate
Dexmethylphenidatum
Dexmetilfenidato
methyl (R)-phenyl[(R)-piperidin-2-yl]acetate

**Chemical Formula:** C
14
H
19
NO
2

**SMILES:** [H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1

**Weight:** Average: 233.3062
Monoisotopic: 233.141578857

**IUPAC Name:** methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate

## Additional Information

### Modality

Small Molecule

### Patents

Patent Number
Pediatric Extension
Expires (estimated)
Region
US5908850
No
1999-06-01
2015-12-04
US
US6355656
No
2002-03-12
2015-12-04
US
US6528530
No
2003-03-04
2015-12-04
US
US6228398
No
2001-05-08
2019-11-01
US
US6635284
No
2003-10-21
2015-12-04
US
US7431944
No
2008-10-07
2015-12-04
US
US5837284
No
1998-11-17
2015-12-04
US
US6730325
No
2004-05-04
2019-11-01
US
US8062667
No
2011-11-22
2029-03-29
US
US8465765
No
2013-06-18
2031-02-15
US
US8778390
No
2014-07-15
2031-02-15
US
US8563033
No
2013-10-22
2031-02-15
US
US8956649
No
2015-02-17
2031-02-15
US
US9040083
No
2015-05-26
2031-02-15
US
US8287903
No
2012-10-16
2031-02-15
US
US7438930
Yes
2008-10-21
2020-06-16
US
US9066869
Yes
2015-06-30
2020-06-16
US
US7247318
Yes
2007-07-24
2020-06-16
US
US7083808
Yes
2006-08-01
2020-06-16
US
US6419960
Yes
2002-07-16
2020-06-16
US
US8580310
Yes
2013-11-12
2020-06-16
US
US9801823
Yes
2017-10-31
2020-06-16
US
US10039719
Yes
2018-08-07
2020-06-16
US
US9498447
No
2016-11-22
2032-03-23
US
US9283214
No
2016-03-15
2032-03-23
US
US9023389
No
2015-05-05
2032-03-23
US
US8927010
No
2015-01-06
2032-03-23
US
US9028868
No
2015-05-12
2032-03-23
US
US9034902
No
2015-05-19
2032-03-23
US
US9603809
No
2017-03-28
2032-03-23
US
US8916588
No
2014-12-23
2032-03-23
US
US10182995
No
2019-01-22
2032-03-23
US
US10111839
No
2018-10-30
2035-10-30
US
US9974752
No
2018-05-22
2035-10-30
US
US10292939
No
2019-05-21
2035-10-30
US
US10292938
No
2019-05-21
2035-10-30
US
US10292937
No
2019-05-21
2032-03-23
US
US10449159
No
2019-10-22
2035-10-30
US
US10463624
No
2019-11-05
2019-12-16
US
US10512613
No
2019-12-24
2035-10-30
US
US10500162
No
2019-12-10
2035-10-30
US
US10507186
No
2019-12-17
2035-10-30
US
US10512612
No
2019-12-24
2035-10-30
US
US10568841
No
2020-02-25
2035-10-30
US
US10617651
No
2020-04-14
2032-03-23
US
US10688060
No
2020-06-23
2035-10-30
US
US10722473
No
2020-07-28
2038-11-19
US
US10881618
No
2021-01-05
2032-03-23
US
US10905652
No
2021-02-02
2032-03-23
US
US10858341
No
2020-12-08
2037-12-09
US
US10954213
No
2021-03-23
2037-12-09
US
US10584112
No
2020-03-10
2037-12-09
US
US9079928
No
2015-07-14
2032-07-27
US
US10584113
No
2020-03-10
2037-12-09
US
US10759778
No
2020-09-01
2037-12-09
US

### Indicated Conditions

1

### Phase 0

1

### Phase 1

11

### Phase 2

7

### Phase 3

19

### Phase 4

8

### Therapeutic Categories

Central Nervous System
Stimulants

### Summary

Dexmethylphenidate
is a norepinephrine-dopamine reuptake inhibitor used in the treatment of ADHD in conjunction with other therapies.

### Brand Names

Azstarys, Focalin

### Generic Name

Dexmethylphenidate

### DrugBank Accession Number

DB06701

### Groups

Approved, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Dexmethylphenidate (DB06701)
×
Close

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Management of
Adhd
••••••••••••
Create Account
••••••• ••••••• •••••••• •••••••
Create Account

### Mechanism of action

Methylphenidate inhibits dopamine and norepinephrine reuptake transporters in synapses, especially in the thalamus and striatum
5
. One study shows no detectable difference in the caudal prefrontal cortex of treated or untreated monkeys, though multiple rat studies show activity on the prefrontal cortex
5
. Imaging of human brains after administration of methylphenidate shows changes to blood flow of various regions of the brain including the striatum, supplementary motor area, and posterior parietal cortex
5
.
Target
Actions
Organism
A
Sodium-dependent dopamine transporter
inhibitor
Humans
A
Sodium-dependent noradrenaline transporter
inhibitor
Humans
U
Sodium-dependent serotonin transporter
inhibitor
Humans

### Volume of distribution

2.65L/kg when administered intravenously
4
.

### Protein binding

12-15% of dexmethylphenidate is protein bound
Label
. However, other studies have observed 15.2±5.2% protein binding in children and 16.2±1.1% in adults
4
.

### Route of elimination

Dexmethylphenidate is mainly eliminated renally
4
. After 48 hours, 90% of the dose is collected in the urine and 3.3% is collected from feces
4
.

### Clearance

0.40L/hr/kg following an intravenous dose and a renal clearance of 0.005L/hr/kg
4
,
Label
.

### Product Ingredients

Ingredient
UNII
CAS
InChI Key
Dexmethylphenidate hydrochloride
1678OK0E08
19262-68-1
JUMYIBMBTDDLNG-OJERSXHUSA-N

### Product Images

Previous
Next

### International/Other Brands

Attenade (Celgene)

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Focalin
Tablet
2.5 mg/1
Oral
Novartis Farma S.P.A.
2001-11-30
2026-07-31
US
Focalin
Tablet
10 mg/1
Oral
Sandoz Inc
2001-11-30
2027-09-30
US
Focalin
Tablet
10 mg/1
Oral
Novartis Farma S.P.A.
2001-11-30
2026-07-31
US
Focalin
Tablet
5 mg/1
Oral
Sandoz Inc
2001-11-30
2027-09-30
US
Focalin
Tablet
5 mg/1
Oral
Novartis Farma S.P.A.
2001-11-30
2026-07-31
US

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Dexmethylphenidate HCl
Capsule
30 mg/1
Oral
Adare Pharmaceuticals Inc
2018-11-01
Not applicable
US
Dexmethylphenidate HCl
Capsule
15 mg/1
Oral
Adare Pharmaceuticals Inc
2018-11-01
Not applicable
US
Dexmethylphenidate HCl
Capsule
40 mg/1
Oral
Adare Pharmaceuticals Inc
2018-11-01
Not applicable
US
Dexmethylphenidate HCl
Capsule
25 mg/1
Oral
Adare Pharmaceuticals Inc
2018-11-01
Not applicable
US
Dexmethylphenidate HCl
Capsule
10 mg/1
Oral
Adare Pharmaceuticals Inc
2018-11-01
Not applicable
US

### Mixture Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Azstarys
Dexmethylphenidate hydrochloride
(7.8 mg/1)
+
Serdexmethylphenidate chloride
(39.2 mg/1)
Capsule
Oral
Corium, LLC.
2021-07-16
Not applicable
US
Azstarys
Dexmethylphenidate hydrochloride
(5.2 mg/1)
+
Serdexmethylphenidate chloride
(26.1 mg/1)
Capsule
Oral
Corium, LLC.
2021-07-16
Not applicable
US
Azstarys
Dexmethylphenidate hydrochloride
(10.4 mg/1)
+
Serdexmethylphenidate chloride
(52.3 mg/1)
Capsule
Oral
Corium, LLC.
2021-07-16
Not applicable
US

### ATC Codes

N06BA11 — Dexmethylphenidate
N06BA — Centrally acting sympathomimetics
N06B — PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06 — PSYCHOANALEPTICS
N — NERVOUS SYSTEM
N06BA15 — Dexmethylphenidate and serdexmethylphenidate
N06BA — Centrally acting sympathomimetics
N06B — PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06 — PSYCHOANALEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Agents that produce hypertension
Antidepressive Agents
Central Nervous System Agents
Central Nervous System Depressants
Central Nervous System Stimulants
Central Nervous System Stimulation
Centrally Acting Sympathomimetics
Combined Inhibitors of Serotonin/Norepinephrine Reuptake
Dopamine Agents
Dopamine Uptake Inhibitors
Membrane Transport Modulators
Methylphenidate and isomer
Nervous System
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Phenylacetates
Piperidines
Psychoanaleptics
Psychostimulants, Agents Used for ADHD and Nootropics
Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
Serotonin Agents
Serotonin Modulators

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Aralkylamines
Alternative Parents
Piperidines
/
Benzene and substituted derivatives
/
Methyl esters
/
Amino acids and derivatives
/
Monocarboxylic acids and derivatives
/
Dialkylamines
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
show 1 more
Substituents
Amino acid or derivatives
/
Aralkylamine
/
Aromatic heteromonocyclic compound
/
Azacycle
/
Benzenoid
/
Carbonyl group
/
Carboxylic acid derivative
/
Carboxylic acid ester
/
Hydrocarbon derivative
/
Methyl ester
/
Monocarboxylic acid or derivatives
/
Monocyclic benzene moiety
/
Organic oxide
/
Organic oxygen compound
/
Organoheterocyclic compound
/
Organooxygen compound
/
Organopnictogen compound
/
Piperidine
/
Secondary aliphatic amine
/
Secondary amine
show 10 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
methyl phenyl(piperidin-2-yl)acetate (
CHEBI:51860
)

### Kingdom

Organic compounds

### Super Class

Organic nitrogen compounds

### Class

Organonitrogen compounds

### Sub Class

Amines

### Direct Parent

Aralkylamines

### Alternative Parents

Piperidines
/
Benzene and substituted derivatives
/
Methyl esters
/
Amino acids and derivatives
/
Monocarboxylic acids and derivatives
/
Dialkylamines
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
show 1 more

### Substituents

Amino acid or derivatives
/
Aralkylamine
/
Aromatic heteromonocyclic compound
/
Azacycle
/
Benzenoid
/
Carbonyl group
/
Carboxylic acid derivative
/
Carboxylic acid ester
/
Hydrocarbon derivative
/
Methyl ester
/
Monocarboxylic acid or derivatives
/
Monocyclic benzene moiety
/
Organic oxide
/
Organic oxygen compound
/
Organoheterocyclic compound
/
Organooxygen compound
/
Organopnictogen compound
/
Piperidine
/
Secondary aliphatic amine
/
Secondary amine
show 10 more

### Molecular Framework

Aromatic heteromonocyclic compounds

### External Descriptors

methyl phenyl(piperidin-2-yl)acetate (
CHEBI:51860
)

### Affected organisms

Humans and other mammals

### UNII

M32RH9MFGP

### CAS number

40431-64-9

### InChI Key

DUGOZIWVEXMGBE-CHWSQXEVSA-N

### InChI

InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m1/s1

### Synthesis Reference

Arie Gutman, "Process for the preparation of dexmethylphenidate hydrochloride." U.S. Patent US20040180928, issued September 16, 2004.
US20040180928

### General References

Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, Hurley TD, Bosron WF: Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther. 2004 Aug;310(2):469-76. doi: 10.1124/jpet.104.067116. Epub 2004 Apr 13. [
Article
]
Liu F, Minami H, Silva RR: Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder. Neuropsychiatr Dis Treat. 2006 Dec;2(4):467-73. [
Article
]
Modi NB, Wang B, Noveck RJ, Gupta SK: Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J Clin Pharmacol. 2000 Oct;40(10):1141-9. [
Article
]
Kimko HC, Cross JT, Abernethy DR: Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet. 1999 Dec;37(6):457-70. doi: 10.2165/00003088-199937060-00002. [
Article
]
Tremblay S, Pieper F, Sachs A, Joober R, Martinez-Trujillo J: The Effects of Methylphenidate (Ritalin) on the Neurophysiology of the Monkey Caudal Prefrontal Cortex. eNeuro. 2019 Mar 4;6(1). pii: eN-NWR-0371-18. doi: 10.1523/ENEURO.0371-18.2018. eCollection 2019 Jan-Feb. [
Article
]
Focalin (Dexmethylphenidate) FDA Label [
File
]
Dexmethylphenidate XR FDA Label [
File
]

### External Links

Human Metabolome Database
HMDB0015647
PubChem Compound
154101
PubChem Substance
99443255
ChemSpider
135807
BindingDB
50062915
RxNav
352372
ChEBI
51860
ChEMBL
CHEMBL827
ZINC
ZINC000000896711
PharmGKB
PA10054
PDBe Ligand
A1D5U
Wikipedia
Dexmethylphenidate

### Human Metabolome Database

HMDB0015647

### PubChem Compound

154101

### PubChem Substance

99443255

### ChemSpider

135807

### BindingDB

50062915

### RxNav

352372

### ChEBI

51860

### ChEMBL

CHEMBL827

### ZINC

ZINC000000896711

### PharmGKB

PA10054

### PDBe Ligand

A1D5U

### Wikipedia

Dexmethylphenidate

### PDB Entries

8y2g

### FDA label

Download
(1.11 MB)

### MSDS

Download
(242 KB)

### Dosage Forms

Form
Route
Strength
Tablet
Oral
10 mg
Tablet
Oral
2.5 mg
Tablet
Oral
5 mg
Capsule
Oral
Capsule
Oral
10 mg/1
Capsule
Oral
15 mg/1
Capsule
Oral
20 mg/1
Capsule
Oral
25 mg/1
Capsule
Oral
30 mg/1
Capsule
Oral
35 mg/1
Capsule
Oral
40 mg/1
Capsule
Oral
5 mg/1
Capsule, extended release
Oral
25 mg/1
Capsule, extended release
Oral
30 mg/1
Capsule, extended release
Oral
35 mg/1
Tablet
Oral
10 mg/1
Tablet
Oral
2.5 mg/1
Tablet
Oral
5 mg/1
Capsule, extended release
Oral
15 mg/1
Capsule, extended release
Oral
40 mg/1
Capsule, extended release
Oral
10 mg/1
Capsule, extended release
Oral
20 mg/1
Capsule, extended release
Oral
5 mg/1

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
>203
[MSDS]

### Predicted Properties

Property
Value
Source
logP
2.25
Chemaxon
pKa (Strongest Basic)
9.09
Chemaxon
Physiological Charge
1
Chemaxon
Hydrogen Acceptor Count
2
Chemaxon
Hydrogen Donor Count
1
Chemaxon
Polar Surface Area
38.33 Å
2
Chemaxon
Rotatable Bond Count
4
Chemaxon
Refractivity
66.73 m
3
·mol
-1
Chemaxon
Polarizability
26.15 Å
3
Chemaxon
Number of Rings
2
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
Yes
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9941
Blood Brain Barrier
+
0.9663
Caco-2 permeable
+
0.6564
P-glycoprotein substrate
Substrate
0.5466
P-glycoprotein inhibitor I
Non-inhibitor
0.7964
P-glycoprotein inhibitor II
Non-inhibitor
0.9601
Renal organic cation transporter
Inhibitor
0.532
CYP450 2C9 substrate
Non-substrate
0.7897
CYP450 2D6 substrate
Non-substrate
0.9116
CYP450 3A4 substrate
Non-substrate
0.5985
CYP450 1A2 substrate
Non-inhibitor
0.592
CYP450 2C9 inhibitor
Non-inhibitor
0.897
CYP450 2D6 inhibitor
Non-inhibitor
0.5245
CYP450 2C19 inhibitor
Non-inhibitor
0.9265
CYP450 3A4 inhibitor
Non-inhibitor
0.8539
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.9328
Ames test
Non AMES toxic
0.9133
Carcinogenicity
Non-carcinogens
0.9648
Biodegradation
Not ready biodegradable
0.5759
Rat acute toxicity
2.7718 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.8466
hERG inhibition (predictor II)
Non-inhibitor
0.7491
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-0089-9610000000-8e4c1241e36274356032
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-001i-4190000000-fef041a243a714b6bcaf
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-001r-9120000000-b5db236b260a5c8e3151
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0089-3790000000-1d766bcf3e602b1e5a3b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-014l-4920000000-775709067ea58a06f13b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-052f-9200000000-bc89321ee3ca13496a53
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9100000000-da8a2bb07df6a5f27f1a
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
163.9031387
predicted
DarkChem Lite v0.1.0
[M-H]-
154.58199
predicted
DeepCCS 1.0 (2019)
[M+H]+
164.2831387
predicted
DarkChem Lite v0.1.0
[M+H]+
156.94
predicted
DeepCCS 1.0 (2019)
[M+Na]+
164.1948387
predicted
DarkChem Lite v0.1.0
[M+Na]+
163.03313
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

No

### Actions

Substrate

### General Function

Serotonin transporter that cotransports serotonin with one Na(+) ion in exchange for one K(+) ion and possibly one proton in an overall electroneutral transport cycle. Transports serotonin across the plasma membrane from the extracellular compartment to the cytosol thus limiting serotonin intercellular signaling (PubMed:10407194, PubMed:12869649, PubMed:21730057, PubMed:27049939, PubMed:27756841, PubMed:34851672). Essential for serotonin homeostasis in the central nervous system. In the developing somatosensory cortex, acts in glutamatergic neurons to control serotonin uptake and its trophic functions accounting for proper spatial organization of cortical neurons and elaboration of sensory circuits. In the mature cortex, acts primarily in brainstem raphe neurons to mediate serotonin uptake from the synaptic cleft back into the pre-synaptic terminal thus terminating serotonin signaling at the synapse (By similarity). Modulates mucosal serotonin levels in the gastrointestinal tract through uptake and clearance of serotonin in enterocytes. Required for enteric neurogenesis and gastrointestinal reflexes (By similarity). Regulates blood serotonin levels by ensuring rapid high affinity uptake of serotonin from plasma to platelets, where it is further stored in dense granules via vesicular monoamine transporters and then released upon stimulation (PubMed:17506858, PubMed:18317590). Mechanistically, the transport cycle starts with an outward-open conformation having Na1(+) and Cl(-) sites occupied. The binding of a second extracellular Na2(+) ion and serotonin substrate leads to structural changes to outward-occluded to inward-occluded to inward-open, where the Na2(+) ion and serotonin are released into the cytosol. Binding of intracellular K(+) ion induces conformational transitions to inward-occluded to outward-open and completes the cycle by releasing K(+) possibly together with a proton bound to Asp-98 into the extracellular compartment. Na1(+) and Cl(-) ions remain bound throughout the transport cycle (PubMed:10407194, PubMed:12869649, PubMed:21730057, PubMed:27049939, PubMed:27756841, PubMed:34851672). Additionally, displays serotonin-induced channel-like conductance for monovalent cations, mainly Na(+) ions. The channel activity is uncoupled from the transport cycle and may contribute to the membrane resting potential or excitability (By similarity)

### Specific Function

hydrolase activity

### Gene Name

CES1A1a

### Uniprot ID

Q6LAP9

### Uniprot Name

Carboxylesterase

### Molecular Weight

1908.25 Da

`,
  "protestkit": `{
  "url": "https://drugs.tripsit.me/focalin",
  "experiencesUrl": "https://www.reddit.com/search/?q=Dexmethylphenidate",
  "name": "Dexmethylphenidate",
  "aliases": [
    "dextromethylphenidate"
  ],
  "aliasesStr": "dextromethylphenidate",
  "summary": "The psychoactive isomer of methylphenidate, mostly used to treat ADHD. Twice as potent as methylphenidate, and is said to have cleaner psychostimulant effects with fewer side effects.",
  "reagents": null,
  "classes": {
    "chemical": [],
    "psychoactive": []
  },
  "toxicity": null,
  "addictionPotential": null,
  "tolerance": null,
  "crossTolerances": null,
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Light",
          "value": "10-20mg"
        },
        {
          "name": "Common",
          "value": "20-30mg"
        },
        {
          "name": "Strong",
          "value": "30-40mg"
        },
        {
          "name": "Heavy",
          "value": "40-50mg"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.75 - 1.5 hours"
        },
        {
          "name": "Duration",
          "value": "9.0 - 12.0 hours"
        },
        {
          "name": "After effects",
          "value": "1.0 - 12.0 hours"
        }
      ]
    }
  ],
  "interactions": null,
  "effects": null,
  "categorized_effects": {
    "Physical effects": [],
    "Mental effects": [],
    "Sensory effects": [],
    "Uncategorized effects": []
  }
}`,
  "tripsit-factsheets": `# Dexmethylphenidate
*Source: TripSit Factsheets (tripsit.me)*

## Summary

The psychoactive isomer of methylphenidate, the drug is mainly used to treat ADHD. It is 2x as potent as methylphenidate, and is reported to have cleaner psychostimulant effects with fewer side effects.

## Classification
- **Categories:** stimulant, habit-forming, common
- **Also known as:** dexmethylphenidate, dextromethylphenidate

## Dosage

### Oral
- **Common:** 20-30mg
- **Heavy:** 40-50mg
- **Light:** 10-20mg
- **Strong:** 30-40mg

## Duration
- **Onset:** 45-90 minutes
- **Duration:** 9-12 hours
- **After Effects:** 1-12 hours
`,
  "wikipedia": `# Dexmethylphenidate
*Source: https://en.wikipedia.org/wiki/Dexmethylphenidate*

Dexmethylphenidate, sold under the brand name Focalin among others, is a central nervous system (CNS) stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD) in those over the age of five years. It is taken by mouth. The immediate-release formulation lasts up to five hours while the extended-release formulation lasts up to twelve hours. It is the more active enantiomer of methylphenidate. Methylphenidate has been shown to be more effective than atomoxetine and superior in treating ADHD symptoms when compared.  
Common side effects include abdominal pain, loss of appetite, and fever. Serious side effects may include psychosis, sudden cardiac death, mania, anaphylaxis, seizures, and priapism. Safety during pregnancy and breastfeeding is unclear.
Dexmethylphenidate was approved for medical use in the United States in 2001. It is available as a generic medication. In 2023, it was the 127th most commonly prescribed medication in the United States, with more than 4 million prescriptions.

## Medical uses

Dexmethylphenidate is used as a treatment for attention deficit hyperactivity disorder (ADHD), usually along with psychological, educational, behavioral or other forms of treatment. It is proposed that stimulants help ameliorate the symptoms of ADHD by making it easier for the user to concentrate, avoid distraction, and control behavior. Placebo-controlled trials have shown that once-daily dexmethylphenidate XR was effective and generally well tolerated.
Improvements in ADHD symptoms in children were significantly greater for dexmethylphenidate XR versus placebo. It also showed greater efficacy than osmotic controlled-release oral delivery system (OROS) methylphenidate over the first half of the laboratory classroom day but assessments late in the day favoured OROS methylphenidate.

## Contraindications

Methylphenidate is contraindicated for individuals with agitation, tics, glaucoma, heart defects or a hypersensitivity to any ingredients contained in methylphenidate pharmaceuticals.
Pregnant women are advised to only use the medication if the benefits outweigh the potential risks. Not enough human studies have been conducted to conclusively demonstrate an effect of methylphenidate on fetal development. In 2018, a review concluded that it has not been teratogenic in rats and rabbits, and that it "is not a major human teratogen".

### Hypertension

Patients with preexisting high blood pressure or hypertension are at an increased risk of having symptoms worsen due to the use of CNS stimulants.

### Cardiac disease

Sudden death has been reported in patients taking CNS stimulants with cardiac structural abnormalities, arrhythmias, coronary disease, or other forms of cardiac disease. Careful assessment and adjustments to dosage are recommended.

### Glaucoma

Dexmethylphenidate can increase intraocular pressure(IOP) due to dilation of the pupils. In patients with preexisting glaucoma, IOP can cause further damage to the optic nerve.

## Adverse effects

Products containing dexmethylphenidate have a side effect profile comparable to those containing methylphenidate.

The most common side effects associated with methylphenidate (in standard and extended-release formulations) are appetite loss, dry mouth, anxiety/nervousness, nausea, and insomnia. Gastrointestinal adverse effects may include abdominal pain and weight loss. Nervous system adverse effects may include akathisia (agitation/restlessness), irritability, dyskinesia (tics), lethargy (drowsiness/fatigue), and dizziness. Cardiac adverse effects may include palpitations, changes in blood pressure, and heart rate (typically mild), and tachycardia (rapid heart rate). Ophthalmologic adverse effects may include blurred vision and dry eyes, with less frequent reports of diplopia and mydriasis. In some cases, tolerance might be an issue with stimulants like methylphenidate.
Results from a 2024 systematic review showed that methylphenidate significantly improves ADHD symptoms and broadband measures but can cause appetite suppression and other adverse events in children and adolescents. Smokers with ADHD who take methylphenidate may increase their nicotine dependence, and smoke more often than before they began using methylphenidate, with increased nicotine cravings and an average increase of 1.3 cigarettes per day.
There is some evidence of mild reductions in height with prolonged treatment in children. This has been estimated at 1 centimetre (0.4 in) or less per year during the first three years with a total decrease of 3 centimetres (1.2 in) over 10 years.
Hypersensitivity (including skin rash, urticaria, and fever) is sometimes reported when using transdermal methylphenidate. The Daytrana patch has a much higher rate of skin reactions than oral methylphenidate.
Methylphenidate can worsen psychosis in people who are psychotic, and in very rare cases it has been associated with the emergence of new psychotic symptoms. It should be used with extreme caution in people with bipolar disorder due to the potential induction of mania or hypomania. There have been very rare reports of suicidal ideation, but some authors claim that evidence does not support a link. Logorrhea is occasionally reported and visual hallucinations are very rarely reported. Priapism is a very rare adverse event that can be potentially serious.
U.S. Food and Drug Administration-commissioned studies in 2011 indicate that in children, young adults, and adults, there is no association between serious adverse cardiovascular events (sudden death, heart attack, and stroke) and the medical use of methylphenidate or other ADHD stimulants.
Because some adverse effects may only emerge during chronic use of methylphenidate, a constant watch for adverse effects is recommended.
A 2018 Cochrane review found the drug "may be associated with a number of serious adverse events as well as a large number of non‐serious adverse events in children and adolescents". It stated "it is not possible to accurately estimate the actual risk of adverse events" because the quality of evidence in the 260 studies assessed was "very low".

### Overdose

The symptoms of a moderate acute overdose of methylphenidate primarily arise from central nervous system overstimulation; these symptoms include: vomiting, nausea, agitation, tremors, hyperreflexia, muscle twitching, euphoria, confusion, hallucinations, delirium, hyperthermia, sweating, flushing, headache, tachycardia, heart palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. A severe overdose may involve symptoms such as hyperpyrexia, sympathomimetic toxidrome, convulsions, paranoia, stereotypy (a repetitive movement disorder), rhabdomyolysis, coma, and circulatory collapse.
A methylphenidate overdose is rarely fatal with appropriate care. Following injection of methylphenidate tablets into an artery, severe toxic reactions involving abscess formation and necrosis have been reported.
Treatment of a methylphenidate overdose typically involves the administration of benzodiazepines, with antipsychotics, α-adrenoceptor agonists and propofol serving as second-line therapies.

### Addiction and dependence

Methylphenidate displays addiction and dependence liability similar to that of amphetamine. It has moderate liability among addictive drugs; addiction and psychological dependence may occur, particularly when methylphenidate is used at high doses or in non-medical contexts. Methylphenidate has the potential to induce euphoria due to its pharmacodynamic effect (i.e., dopamine reuptake inhibition) in the brain's reward system. At therapeutic doses, ADHD stimulants do not sufficiently activate the reward system; consequently, when taken as directed in doses that are commonly prescribed for the treatment of ADHD, methylphenidate use lacks the capacity to cause an addiction.

#### Biomolecular mechanisms

Repeated high-dose administration of methylphenidate has been shown to induce the expression of ΔFosB in D1-type medium spiny neurons of the nucleus accumbens, with accumbal ΔFosB levels accumulating over the long-term with chronic exposure due to its unusually long half-life. Overexpression (i.e., a persistently excessive level of gene expression) of ΔFosB in this subset of neurons is a necessary and sufficient biomolecular mechanism for many of the neural adaptations and reward-related behavioral changes associated with drug addiction (e.g., reward sensitization and compulsive drug self-administration).

## Interactions

Methylphenidate (MPH) is widely described in the pharmacological literature as being metabolized primarily, and almost exclusively, by carboxylesterase 1 into its inactive metabolite, ritalinic acid (RA). However, enzyme-induction and inhibition data, together with structural biochemical analyses of MPH and related analogues, challenge this CES1-only framework. Accumulating evidence strongly indicates that CYP2B6, CYP2E1, and CYP3A4 contribute substantially to the clearance and metabolic fate of methylphenidate.
Studies examining CYP2B6 show that induction by agents such as carbamazepine produces a marked reduction in circulating methylphenidate concentrations, whereas inhibition—including reports involving turmeric constituents—results in elevated plasma levels and a prolonged duration of action. CYP2E1 has been shown to catalyse α-hydroxylation of the methylphenidate ester side chain, a reaction that promotes its spontaneous degradation to ritalinic acid; inhibition of this isoenzyme, most notably by alcohol, correspondingly increases methylphenidate exposure. CYP3A4 also plays a clinically relevant role, particularly in the presence of ethanol, wherein it mediates the transesterification of methylphenidate to ethylphenidate, an active metabolite. Induction of CYP3A4, including observations associated with glucose-stimulated pathways, increases metabolic flux through this route and can alter drug levels while shortening the duration of effect.
Taken together, these findings indicate that the classical view of methylphenidate metabolism as governed solely by CES1 is incomplete. A multi-enzyme model better accounts for observed clinical pharmacokinetics and drug–drug interactions, with CYP2B6 serving as a major clearance pathway, CYP2E1 generating ritalinic acid through α-hydroxylation, and CYP3A4 producing ethylphenidate in ethanol-containing conditions.
Methylphenidate may inhibit the metabolism of vitamin K anticoagulants, certain anticonvulsants, and some antidepressants (tricyclic antidepressants, and selective serotonin reuptake inhibitors). Concomitant administration may require dose adjustments, possibly assisted by monitoring of plasma drug concentrations. There are several case reports of methylphenidate inducing serotonin syndrome with concomitant administration of antidepressants.
When methylphenidate is coingested with ethanol, a metabolite called ethylphenidate is formed via hepatic transesterification, not unlike the hepatic formation of cocaethylene from cocaine and ethanol. The reduced potency of ethylphenidate and its minor formation means it does not contribute to the pharmacological profile at therapeutic doses, and even in overdose cases, ethylphenidate concentrations remain negligible.
Coingestion of alcohol also increases the blood plasma levels of d-methylphenidate by up to 40%.
Liver toxicity from methylphenidate is extremely rare, but limited evidence suggests that intake of β-adrenergic agonists with methylphenidate may increase the risk of liver toxicity.

## Pharmacology

### Pharmacokinetcs

Dexmethylphenidate has a 4–6 hour duration of effect. A long-acting formulation, Focalin XR, which spans 12 hours is also available and has been shown to be as effective as DL (dextro-, levo-)-TMP (threo-methylphenidate) XR (extended release) (Concerta, Ritalin LA), with flexible dosing and good tolerability. It has also been demonstrated to reduce ADHD symptoms in both children and adults. d-MPH  has a similar side-effect profile to MPH and can be administered without regard to food intake.
CTx-1301 is an experimental medication that is an extended-release formulation of dexmethylphenidate that has a half life more than an hour longer than extended-release dexmethylphenidate (d-MPH-ER). It is under development for ADHD.

### Mechanism of action

Methylphenidate is a catecholamine reuptake inhibitor that indirectly increases catecholaminergic neurotransmission by inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), which are responsible for clearing catecholamines from the synapse, particularly in the striatum and meso-limbic system. Moreover, it is thought to "increase the release of these monoamines into the extraneuronal space."
In Vitro studies show Methylphenidate possesses weak affinity for 5-HT1A receptors and acts as a partial agonist.
Methylphenidate, by acting as a negative allosteric modulator of the DAT transporter, prevents dopamine molecules from being absorbed into DAT. This modulation makes DAT less efficient at coupling sodium and chloride gradients to drive inward dopamine transport. Instead, DAT is shifted to the outward-facing state, making it harder to use the sodium gradient (positive charge that normally pulls dopamine inward) and the chloride gradient (negative charge that normally stabilizes the cycle). In this outward conformation, dopamine is “pulled” from the cytosol into the synapse while reuptake is blocked. By keeping DAT outward-facing, sodium coupling is disrupted, chloride coupling is decreased, and inward turnover destabilized. This biases DAT toward outward release, allowing dopamine to leak out without fully coupling to ions. As a result, dopamine is no longer tightly gated by sodium binding, and the firing rate of dopamine from DAT increases.
Methylphenidate increases extracellular dopamine not only by competitively inhibiting reuptake at the dopamine transporter (DAT), but also by modulating DAT conformation through non-substrate-mediated mechanisms. Specifically, methylphenidate acts as a negative allosteric modulator (NAM) at the presynaptic Dopamine Transporter, stabilizing the transporter in its outward-facing conformation. This shift alters the electrochemical gradient and transporter kinetics in a way that promotes dopamine efflux from the presynaptic cytosol into the synaptic cleft even though methylphenidate is not a DAT substrate. This presynaptic Dopamine Transporter Negative allosteric modulation driven efflux amplifies phasic dopamine release and uniquely increases phasic firing rate. This of course in contrast to amphetamines, which reverse DAT via substrate competition and concurrently reduce the dopamine transporter firing rate. Notably, methylphenidate has been shown in studies to induce up to a 500% increase in dopamine release, comparable in magnitude to methamphetamine, though via a non-vesicular, transporter-mediated mechanism. Its 2–3-fold higher DAT binding affinity compared to cocaine may contribute to its more potent and sustained dopaminergic effect.
This is identical in process to how cocaine leads to an increase in dopamine firing rate and dopamine release into the synapse. However because methylphenidate binds to the DAT transporter with 2-3 fold higher affinity than cocaine this leads to methylphenidate being more powerful as a DAT negative allosteric modulator. Producing a robust dopamine release of 500% equivalent to methamphetamine.
Although four stereoisomers of methylphenidate (MPH) are possible, only the threo diastereoisomers are used in modern practice. There is a high eudysmic ratio between the SS and RR enantiomers of MPH. Dexmethylphenidate (d-threo-methylphenidate) is a preparation of the RR enantiomer of methylphenidate. In theory, D-TMP (d-threo-methylphenidate) can be anticipated to be twice the strength of the racemic product.

## Chemistry

Dexmethylphenidate a d-threo isomer of methylphenidate which means both chiral centers are in the R configuration. It possesses a Piperidine ring, Phenyl ring and a Methyl Ester group. It is structurally similar to Dopamine and Norepinephrine due to fact that all three molecules contain a Phenethylamine Moiety. It is this similarity that allows Dexmethylphenidate to bind to the Dopamine Transporter (DAT) and the Norepinephrine Transporter (NET).
`,
};
